PF-Atlas › Clinical Trials › NCT05713292

Pirfenidone in Adult Hospitalized Patients With COVID-19

Pirfenidone Oral Product · Phase 3

Registry ID
NCT05713292
Phase
Phase 3
Status
Completed
Drug / intervention
Pirfenidone Oral Product
Sponsor
Capital Medical University
Start
2022-12-01
Enrollment
168
Locations
1

About this trial

This center intends to conduct a multicenter, randomized, placebo-controlled study to evaluate the effectiveness and safety of Nintedanib ethanesulfonate soft capsule in the treatment of pulmonary fibrosis in patients with moderate to severe COVID-19.

View NCT05713292 on ClinicalTrials.gov →

Explore related

All Pirfenidone Oral Product trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT05713292 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.